Short Interest in Oculis Holding AG (NASDAQ:OCS) Increases By 127.3%

Oculis Holding AG (NASDAQ:OCS) was the recipient of a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 29,100 shares, a growth of 127.3% from the January 31st total of 12,800 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average daily trading volume, of 70,000 shares, the short-interest ratio is currently 0.4 days.

Hedge Funds Weigh In On Oculis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OCS. Bellevue Group AG purchased a new position in Oculis during the fourth quarter valued at approximately $170,000. XTX Topco Ltd bought a new position in Oculis in the 4th quarter valued at $225,000. Geode Capital Management LLC grew its position in shares of Oculis by 12.0% during the 4th quarter. Geode Capital Management LLC now owns 16,744 shares of the company’s stock valued at $284,000 after purchasing an additional 1,800 shares in the last quarter. Citadel Advisors LLC bought a new position in shares of Oculis in the fourth quarter worth $389,000. Finally, Bank of America Corp DE raised its position in shares of Oculis by 58.2% in the fourth quarter. Bank of America Corp DE now owns 28,980 shares of the company’s stock worth $493,000 after buying an additional 10,667 shares in the last quarter. Institutional investors own 22.30% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Chardan Capital reaffirmed a “buy” rating and set a $28.00 target price on shares of Oculis in a research report on Tuesday, January 7th. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Oculis in a research report on Monday, January 6th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $28.80.

Oculis Stock Down 0.5 %

NASDAQ OCS traded down $0.10 during mid-day trading on Friday, hitting $19.58. The company’s stock had a trading volume of 38,424 shares, compared to its average volume of 93,908. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01. The company’s 50 day simple moving average is $20.58 and its 200 day simple moving average is $16.50. The firm has a market capitalization of $793.07 million, a price-to-earnings ratio of -10.15 and a beta of -0.24. Oculis has a twelve month low of $10.55 and a twelve month high of $23.08.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.